-
December 6, 8, and 9, 2021: Budget Impact Analysis II: Applications and Design Issues
This course covers the concrete application of the 6-step approach for developing budget impact analyses and provides hands-on learning with two different budget impact models programmed in Excel. The course will review the basics of budget impact analysis, interpretation of results, simplicity versus accuracy and face validity, and how budget impact analyses are used by payers and other decision makers.
-
Virtual ISPOR Europe 2021-On Demand Until January 2
The conference event will provide dedicated content covering the latest trends and topics in HEOR in the European region and globally in a variety of formats including live programming, virtual poster presentations, networking opportunities, a virtual exhibitor gallery, and more, and will include real-time interaction with presenters via Q&A, and in Discussion Rooms.
-
HEOR Theater - External Control Arms Using Real-World Data - Filling a Data Gap
1:00PM - 1:45PM EST
-
HEOR Theater - Demonstrating the Value of Vaccines: Global NITAG and HTA Requirements
12:00PM - 12:45PM EST
-
HEOR Theater - Real World Insights into the US COVID-19 Crisis: New Findings from Analyses of Claims Data
11:00AM - 11:45AM EST
-
HEOR Theater - External Control Arms – The Case for a Standardized Lexicon and Toolkit
10:00AM - 10:45AM EST
-
10 November: Use of Propensity Scores in Observational Studies of Treatment Effects
In observational research, issues of bias and confounding relate to study design and analysis in the setting of non-random treatment assignment where compared subjects might differ substantially with respect to comorbidities.
-
Health Preferences in HTA: Use of Patient and Public Preferences
-
HEOR Theater - Addressing Prenatal Exposures and Outcomes for Regulatory Requirements Using Real-World Data
1:00PM - 1:45PM EST
-
HEOR Theater - Effect Modification in Network Meta-Analysis: Is Population Adjustment Always the Answer?
12:00PM - 12:45PM EST
-
HEOR Theater - Optimizing Research Using Real-World Data During the COVID-19 Pandemic
11:00AM - 11:45AM EST
-
Signal - Episode 5- On-demand until November 30
Join Tom Cassels and Alyssa Jaffe - seasoned venture capital investors with background from the healthcare settings - in discussing the highlights, possible implications and learnings from investment activity for the downstream healthcare decision-making where stakeholders are looking primarily at evidence-based solutions.
-
Evolving Real World Data/Evidence Guidelines and Landscape in China: From Policy to Practice
-
6-7 October: Risk-Sharing/Performance-Based Arrangements for Drugs and Other Medical Products
There is significant and growing interest among both the payers and producers of medical products for arrangements that involve a “pay-for-performance” or “risk-sharing” element.
-
27-28 September: Causal Inference and Causal Diagrams in Big, Real-World Observational Data and Pragmatic Trials
There is significant and growing interest among both the payers and producers of medical products for arrangements that involve a “pay-for-performance” or “risk-sharing” element. These payment schemes involve a plan by which the performance of the product is tracked in a defined patient population over a specified period of time and the level of reimbursement is tied by formula to the outcomes achieved.
-
Health Preference Research in the Context of Gene Therapy in Rare Diseases
-
HEOR Theater - Using Item Banks to Build Condition Specific Static Short Form Outcome Measures
1:00PM - 1:45PM EST
-
HEOR Theater - Health Technology Assessment in 2030: How Methods, Technology and Data will Change the Way Drugs are Reimbursed
12:00PM - 12:45PM EST
-
HEOR Theater - Making the most of the NICE methods updates to optimize evidence generation and global HTA strategy
10:00AM - 10:45AM EST
-
Embedded Clinical Trials: Understanding the Opportunities and Challenges for Real-World Evidence Generation
11:00AM - 12:00PM EST